From a clinical perspective, immediate implications regarding the molecular similarity shared between KRAS wildtype mPDAC and cholangiocarcinoma are limited, as both diseases often receive platinum-based first-line treatment regimens (containing oxaliplatin and cisplatin, respectively). This evidence concerns the gene KRAS and cholangiocarcinoma.